Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2021-000627-12 | EudraCT Number |
Not provided
Not provided
Based on program revaluation and in agreement with the co-development partner the sponsor took the decision to terminate this study.
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Atea Pharmaceuticals, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]), for approximately 6 months after the end of the parent study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants Diagnosed with COVID-19 | Participants were previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]). |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With COVID-19 Symptoms Assessed Through the COVID-19 Symptom Diary up to Month 6 | COVID-19 symptoms were evaluated using the COVID-19 Symptom Diary. The COVID-19 Symptom Diary included the following 14 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, diarrhea, sense of smell over the past 7 days and sense of taste over the past 7 days. The severity of items 1-12 were recorded on a 4-point Likert scale (i.e none/mild/moderate/severe). Items 13-14 were recorded on a 3-point Likert scale (i.e. same as usual/less than usual/no sense). Reported here is the percentage of participants with COVID-19 symptoms (mild/moderate/severe or less than usual/no sense) recorded during week 4 of each month following the baseline assessment. | Month 1 - Week 4, Month 2 - Week 4, Month 3 - Week 4, Month 4 - Week 4, Month 5 - Week 4, Month 6 - Week 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Dyspnea Symptoms Assessment Score Through the Patient Reported Outcomes Measurement Information System - Short Form (PROMIS-SF) - Dyspnea Questionnaire | The PROMIS-SF-Dyspnea Questionnaire is a 10-item questionnaire to evaluate the impact of dyspnea on specific activities. Participants self-assessed the severity of shortness of breath and difficulty of breathing in response to specific activities with a recall of the past 7 days. The PROMIS SF-Dyspnea Severity instrument is scored on a 4-point Likert scale, with an option to indicate that an activity had not been performed. Total score range is 0-30, where a higher score indicates a higher symptom severity of dyspnea. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants enrolled in a RO7496998 (AT-527) study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Hoffmann-La Roche | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto Ave Pulmo | Mar del Plata | B7602DCK | Argentina | |||
| Private Practice Dr Jean Benoit Martinot |
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research\_and\_development/who\_we\_are\_how\_we\_work/clinical\_trials/our\_commitment\_to\_data\_sharing.htm)
Not provided
Not provided
Not provided
Not provided
Not provided
Participants diagnosed with COVID-19, who previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]), were enrolled in this study after the end of the parent study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | All Participants | Participants were previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]). |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 3, 2021 |
Not provided
Not provided
Not provided
| Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6 |
| Respiratory-specific Health-related Quality of Life Score as Assessed by the St. George's Respiratory Questionnaire (SGRQ) | The SGRQ is a 50-item respiratory-specific health-related quality of life instrument that measures health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. Each scale is scored from 0 to 100, and the total score represents the weighted average of these three subscores. Higher scores correspond to worse quality of life. The SGRQ had a recall specification of 4 weeks. | Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6 |
| Percentage of Participants With COVID-19 Related Medically-Attended Visits | COVID-19-related medically-attended visits were defined as hospitalization, ER visit, urgent care visit, physician's office visit, or telemedicine visit with the primary reason for the visit being COVID-19 or COVID-19-related symptoms. | Up to 6 months |
| Percentage of Participants With Death Attributable to Progression of COVID-19 | Up to 6 months |
| Percentage of Participants Re-Infected With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | Reinfection was defined as any nasopharyngeal (NP) swab that was positive for SARS-CoV-2 infection via reverse-transcriptase polymerase chain reaction (RT-PCR), taken when clinically indicated based on symptoms. | Up to 6 months |
| Percentage of Participants With Any Post-Treatment Infection | Post-treatment infections were defined as any adverse event with a primary system organ class of infections and infestations. | Up to 6 months |
| Percentage of Participants With COVID-19-Related Complications | COVID-19 related complications included pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis and/or myocarditis, and cardiac failure. | Up to 6 months |
| Percentage of Participants With Adverse Events (AEs) | An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition not present at baseline or related to a protocol-mandated intervention. | Up to 6 months |
| Erpent |
| 5101 |
| Belgium |
| Medif | Gozée | 6534 | Belgium |
| L2IP -Instituto de Pesquisas Clínicas Ltda. | Brasília | Federal District | 70200-730 | Brazil |
| Chronos Pesquisa Clinica | Taguatinga | Federal District | 72145-450 | Brazil |
| Hospital Nossa Senhora das Graças | Curitiba | Paraná | 80810-040 | Brazil |
| Hospital Agamenon Magalhães | Recife | Pernambuco | 52051-380 | Brazil |
| Conjunto Hospitalar do Mandaqui | São Paulo | São Paulo | 02401-400 | Brazil |
| Aalborg Universitetshospital | Aalborg | 9000 | Denmark |
| Rigshospitalet Copenhagen University Hospital | Copenhagen | DK-2100 | Denmark |
| Sjællands Universitetshospital, Roskilde | Roskilde | 4000 | Denmark |
| Praxis am Ebertplatz | Cologne | 50668 | Germany |
| CIMAB SA de CV | Torreón | Coahuila | 27000 | Mexico |
| Panamerican Clinical Research S.A de C.V. | Guadalajara | Jalisco | 44670 | Mexico |
| Clinstile S.A de C.V. | Mexico City | Mexico CITY (federal District) | 06700 | Mexico |
| PanAmerican Clinical Research, Querétaro | Queréaro | Querétaro | 76230 | Mexico |
| Instituto Jalisciense de Investigacion Clinica S.A. de C.V. | Guadalajara | 44100 | Mexico |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | México | Mexico |
| Prof. Dr. Matei Bals Institute of Infectious Diseases | Bucharest | 021105 | Romania |
| County Hospital Caracal | Caracal | 235200 | Romania |
| Sibiu Emergency Clinical County Hospital | Sibiu | 550245 | Romania |
| Universitätsspital Zürich | Zurich | 8091 | Switzerland |
| Gazi Universitesi Tip Fakultesi | Ankara | 06100 | Turkey (Türkiye) |
| Hacettepe University Medical Faculty | Ankara | 06100 | Turkey (Türkiye) |
| Ankara University Medical Faculty - PPDS | Çankaya | 06590 | Turkey (Türkiye) |
| Ege University Medical Faculty | Izmir | 35100 | Turkey (Türkiye) |
| Karadeniz Technical University Faculty of Medicine | Trabzon | 61080 | Turkey (Türkiye) |
| Municipal Non-profit enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council | Ivano-Frankivsk | Katerynoslav Governorate | 76025 | Ukraine |
| Municipal Non-profit Enterprise "City Clinical Hospital #13" of Kharkiv City Council | Kharkiv | Kharkiv Governorate | 61124 | Ukraine |
| CNPE City Clinical Hospital #6 of DCC | Dnipro | Kholm Governorate | 49074 | Ukraine |
| Medical Center LLC "Harmony of Beauty" | Kyiv | KIEV Governorate | 01135 | Ukraine |
| CNE Kyiv City Clinical Hospital#1 of Exec. Body | Kyiv | KIEV Governorate | 02091 | Ukraine |
| Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail | Kyiv | KIEV Governorate | 03049 | Ukraine |
| Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1 | Vinnytsia | Podolia Governorate | Ukraine |
| Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council | Zaporizhzhia | Tavria Okruha | 69118 | Ukraine |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | Participants were previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Percentage of Participants With COVID-19 Symptoms Assessed through the COVID-19 Symptom Diary | The COVID-19 Symptom Diary included the following 14 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, diarrhea, sense of smell over the past 7 days, sense of taste over the past 7 days. Reported here is the percentage of participants for the following: items 1-12 = mild-severe; items 13-14 = less than usual OR no sense of smell/taste. Baseline is approximately one month after the initial infection. | For the study-specific baseline characteristic the number of participants indicates participants with data available for analysis at baseline. | Number | percentage of participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With COVID-19 Symptoms Assessed Through the COVID-19 Symptom Diary up to Month 6 | COVID-19 symptoms were evaluated using the COVID-19 Symptom Diary. The COVID-19 Symptom Diary included the following 14 items: nasal congestion or runny nose, sore throat, cough, shortness of breath, muscle or body aches, fatigue, headache, chills/sweats, feeling hot or feverish, nausea, vomiting, diarrhea, sense of smell over the past 7 days and sense of taste over the past 7 days. The severity of items 1-12 were recorded on a 4-point Likert scale (i.e none/mild/moderate/severe). Items 13-14 were recorded on a 3-point Likert scale (i.e. same as usual/less than usual/no sense). Reported here is the percentage of participants with COVID-19 symptoms (mild/moderate/severe or less than usual/no sense) recorded during week 4 of each month following the baseline assessment. | The analysis population included all participants enrolled in the study. The number of participants analyzed at each time point includes all participants with data available for the specific time point. All enrolled participants contributed to the outcome measure results. | Posted | Number | percentage of participants | Month 1 - Week 4, Month 2 - Week 4, Month 3 - Week 4, Month 4 - Week 4, Month 5 - Week 4, Month 6 - Week 4 |
|
|
| ||||||||||||||||||||||||||||
| Secondary | Dyspnea Symptoms Assessment Score Through the Patient Reported Outcomes Measurement Information System - Short Form (PROMIS-SF) - Dyspnea Questionnaire | The PROMIS-SF-Dyspnea Questionnaire is a 10-item questionnaire to evaluate the impact of dyspnea on specific activities. Participants self-assessed the severity of shortness of breath and difficulty of breathing in response to specific activities with a recall of the past 7 days. The PROMIS SF-Dyspnea Severity instrument is scored on a 4-point Likert scale, with an option to indicate that an activity had not been performed. Total score range is 0-30, where a higher score indicates a higher symptom severity of dyspnea. | The analysis population included all enrolled participants in the study for whom data were available at each time point as indicated. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6 |
|
| ||||||||||||||||||||||||||||
| Secondary | Respiratory-specific Health-related Quality of Life Score as Assessed by the St. George's Respiratory Questionnaire (SGRQ) | The SGRQ is a 50-item respiratory-specific health-related quality of life instrument that measures health impairment. The questionnaire contains 3 domains: symptoms, activity, and impacts. Items were assessed on various response scales, including a 5-point Likert scale and True/False scale. Each scale is scored from 0 to 100, and the total score represents the weighted average of these three subscores. Higher scores correspond to worse quality of life. The SGRQ had a recall specification of 4 weeks. | The analysis population included all enrolled participants in the study for whom data were available at each time point as indicated. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Month 1, Month 2, Month 3, Month 4, Month 5, Month 6 |
|
| ||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With COVID-19 Related Medically-Attended Visits | COVID-19-related medically-attended visits were defined as hospitalization, ER visit, urgent care visit, physician's office visit, or telemedicine visit with the primary reason for the visit being COVID-19 or COVID-19-related symptoms. | The analysis population included all enrolled participants in the study. | Posted | Number | 97.5% Confidence Interval | percentage of participants | Up to 6 months |
|
| ||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Death Attributable to Progression of COVID-19 | The analysis population included all enrolled participants in the study. | Posted | Number | percentage of participants | Up to 6 months |
|
| ||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Re-Infected With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | Reinfection was defined as any nasopharyngeal (NP) swab that was positive for SARS-CoV-2 infection via reverse-transcriptase polymerase chain reaction (RT-PCR), taken when clinically indicated based on symptoms. | The analysis population included all enrolled participants in the study. | Posted | Number | percentage of participants | Up to 6 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Any Post-Treatment Infection | Post-treatment infections were defined as any adverse event with a primary system organ class of infections and infestations. | The analysis population included all enrolled participants in the study. | Posted | Number | 97.5% Confidence Interval | percentage of participants | Up to 6 months |
|
| ||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With COVID-19-Related Complications | COVID-19 related complications included pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis and/or myocarditis, and cardiac failure. | The analysis population included all enrolled participants in the study. | Posted | Number | 97.5% Confidence Interval | percentage of participants | Up to 6 months |
|
| ||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Adverse Events (AEs) | An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition not present at baseline or related to a protocol-mandated intervention. | The safety population included all enrolled participants in the study. | Posted | Number | percentage of participants | Up to 6 months |
|
|
Up to 6 months
All AEs/Serious AEs continuing/persisting from the parent study or any new AEs with an onset date on or after the first day of enrollment and during this follow-up study are displayed. The safety population included all participants enrolled in the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | All Participants | Participants were previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]). | 0 | 72 | 2 | 72 | 17 | 72 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cataract | Eye disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Arterial occlusive disease | Vascular disorders | MedDRA 24.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Food poisoning | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Toothache | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Chest discomfort | General disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Chest pain | General disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Hangover | General disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Vaccination site pain | General disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Gastroenteritis viral | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| |
| Pharyngitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| |
| Rhinitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| |
| Vaginal infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
| |
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
| |
| Muscle strain | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Tenosynovitis | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Hyposmia | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Taste disorder | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Sneezing | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 24.1 | Systematic Assessment |
|
The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Communications | Hoffmann-La Roche | 800 821-8590 | genentech@druginfo.com |
| Sep 9, 2022 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000094024 | Post-Acute COVID-19 Syndrome |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
|
| Unknown or Not Reported |
|
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Sore Throat |
|
|
| Cough |
|
|
| Shortness of Breath |
|
|
| Muscle or Body Aches |
|
|
| Fatigue |
|
|
| Headache |
|
|
| Chills/Sweats |
|
|
| Feeling Hot or Feverish |
|
|
| Nausea |
|
|
| Vomiting |
|
|
| Diarrhea |
|
|
| Reduction or Loss of Sense of Smell over the Past 7 Days |
|
|
| Reduction or Loss of Sense of Taste over the Past 7 Days |
|
|
|
| Nasal Congestion or Runny Nose: Month 3 - Week 4 |
|
|
| Nasal Congestion or Runny Nose: Month 4 - Week 4 |
|
|
| Nasal Congestion or Runny Nose: Month 5 - Week 4 |
|
|
| Nasal Congestion or Runny Nose: Month 6 - Week 4 |
|
|
| Sore Throat: Month 1 - Week 4 |
|
|
| Sore Throat: Month 2 - Week 4 |
|
|
| Sore Throat: Month 3 - Week 4 |
|
|
| Sore Throat: Month 4 - Week 4 |
|
|
| Sore Throat: Month 5 - Week 4 |
|
|
| Sore Throat: Month 6 - Week 4 |
|
|
| Cough: Month 1 - Week 4 |
|
|
| Cough: Month 2 - Week 4 |
|
|
| Cough: Month 3 - Week 4 |
|
|
| Cough: Month 4 - Week 4 |
|
|
| Cough: Month 5 - Week 4 |
|
|
| Cough: Month 6 - Week 4 |
|
|
| Shortness of Breath: Month 1 - Week 4 |
|
|
| Shortness of Breath: Month 2 - Week 4 |
|
|
| Shortness of Breath: Month 3 - Week 4 |
|
|
| Shortness of Breath: Month 4 - Week 4 |
|
|
| Shortness of Breath: Month 5 - Week 4 |
|
|
| Shortness of Breath: Month 6 - Week 4 |
|
|
| Muscle or Body Aches: Month 1 - Week 4 |
|
|
| Muscle or Body Aches: Month 2 - Week 4 |
|
|
| Muscle or Body Aches: Month 3 - Week 4 |
|
|
| Muscle or Body Aches: Month 4 - Week 4 |
|
|
| Muscle or Body Aches: Month 5 - Week 4 |
|
|
| Muscle or Body Aches: Month 6 - Week 4 |
|
|
| Fatigue: Month 1 - Week 4 |
|
|
| Fatigue: Month 2 - Week 4 |
|
|
| Fatigue: Month 3 - Week 4 |
|
|
| Fatigue: Month 4 - Week 4 |
|
|
| Fatigue: Month 5 - Week 4 |
|
|
| Fatigue: Month 6 - Week 4 |
|
|
| Headache: Month 1 - Week 4 |
|
|
| Headache: Month 2 - Week 4 |
|
|
| Headache: Month 3 - Week 4 |
|
|
| Headache: Month 4 - Week 4 |
|
|
| Headache: Month 5 - Week 4 |
|
|
| Headache: Month 6 - Week 4 |
|
|
| Chills/Sweats: Month 1 - Week 4 |
|
|
| Chills/Sweats: Month 2 - Week 4 |
|
|
| Chills/Sweats: Month 3 - Week 4 |
|
|
| Chills/Sweats: Month 4 - Week 4 |
|
|
| Chills/Sweats: Month 5 - Week 4 |
|
|
| Chills/Sweats: Month 6 - Week 4 |
|
|
| Feeling Hot or Feverish: Month 1 - Week 4 |
|
|
| Feeling Hot or Feverish: Month 2 - Week 4 |
|
|
| Feeling Hot or Feverish: Month 3 - Week 4 |
|
|
| Feeling Hot or Feverish: Month 4 - Week 4 |
|
|
| Feeling Hot or Feverish: Month 5 - Week 4 |
|
|
| Feeling Hot or Feverish: Month 6 - Week 4 |
|
|
| Nausea: Month 1 - Week 4 |
|
|
| Nausea: Month 2 - Week 4 |
|
|
| Nausea: Month 3 - Week 4 |
|
|
| Nausea: Month 4 - Week 4 |
|
|
| Nausea: Month 5 - Week 4 |
|
|
| Nausea: Month 6 - Week 4 |
|
|
| Vomiting: Month 1 - Week 4 |
|
|
| Vomiting: Month 2 - Week 4 |
|
|
| Vomiting: Month 3 - Week 4 |
|
|
| Vomiting: Month 4 - Week 4 |
|
|
| Vomiting: Month 5 - Week 4 |
|
|
| Vomiting: Month 6 - Week 4 |
|
|
| Diarrhea: Month 1 - Week 4 |
|
|
| Diarrhea: Month 2 - Week 4 |
|
|
| Diarrhea: Month 3 - Week 4 |
|
|
| Diarrhea: Month 4 - Week 4 |
|
|
| Diarrhea: Month 5 - Week 4 |
|
|
| Diarrhea: Month 6 - Week 4 |
|
|
| Reduction of Loss of Sense of Smell over the Past 7 Days: Month 1 - Week 4 |
|
|
| Reduction or Loss of Sense of Smell over the Past 7 Days: Month 2 - Week 4 |
|
|
| Reduction or Loss of Sense of Smell over the Past 7 Days: Month 3 - Week 4 |
|
|
| Reduction or Loss of Sense of Smell over the Past 7 Days: Month 4 - Week 4 |
|
|
| Reduction or Loss of Sense of Smell over the Past 7 Days: Month 5 - Week 4 |
|
|
| Reduction or Loss of Sense of Smell over the Past 7 Days: Month 6 - Week 4 |
|
|
| Reduction or Loss of Sense of Taste over the Past 7 Days: Month 1 - Week 4 |
|
|
| Reduction or Loss of Sense of Taste over the Past 7 Days: Month 2 - Week 4 |
|
|
| Reduction or Loss of Sense of Taste over the Past 7 Days: Month 3 - Week 4 |
|
|
| Reduction or Loss of Sense of Taste over the Past 7 Days: Month 4 - Week 4 |
|
|
| Reduction or Loss of Sense of Taste over the Past 7 Days: Month 5 - Week 4 |
|
|
| Reduction or Loss of Sense of Taste over the Past 7 Days: Month 6 - Week 4 |
|
|
|
|
|
| Title |
|---|
| Denominators |
|---|
| Categories |
|---|
|
|
|
|
|